Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €52.59 EUR
Change Today +0.52 / 1.01%
Volume 0.0
I7G On Other Exchanges
EN Paris
As of 12:54 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (I7G) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/31/15 - €64.13
52 Week Low
10/16/14 - €33.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IPSEN (I7G)

Related News

No related news articles were found.

ipsen (I7G) Related Businessweek News

View More BusinessWeek News

ipsen (I7G) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates through two segments, Primary Care and Specialty Care. The company offers drugs in uro-oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and cardiovascular areas. Its products include Decapeptyl, a peptide formulation for injection for the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline, which is used primarily in the treatment of acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation for use in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it offers Smecta, a natural clay-based drug for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan, an oral formulation, which is used for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl products. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. operates as a subsidiary of Mayroy SA.

4,304 Employees
Last Reported Date: 03/30/15
Founded in 1929

ipsen (I7G) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: €1.8M
Deputy Chief Executive Officer
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

ipsen (I7G) Key Developments

Ipsen Appoints Stéphane Bessette as Executive Vice President, Human Resources

Ipsen announced the appointment of Stéphane Bessette as Executive Vice President, Human Resources of the Ipsen Group, as of October 1, 2015. He will report to Christel Bories, Deputy Chief Executive Officer of Ipsen, and will sit on the Executive Committee. Stéphane has over 11 years of experience in the medical device sector, working for Sorin Group. Since 2007, he was leading its global Human Resources function, based in Milan, Italy and made a large contribution to Sorin's expansion worldwide.

Ipsen S.A. Presents at The Euromoney/GlobalCapital Corporate Summit 2015, Sep-29-2015 12:50 PM

Ipsen S.A. Presents at The Euromoney/GlobalCapital Corporate Summit 2015, Sep-29-2015 12:50 PM. Venue: Paris, France. Speakers: Anne Gobert, Vice President Treasury, Financing and Credit Management.

Ipsen Announces Positive Phase 3 Results for Upper Limb Spasticity Treatment

Ipsen reported its phase 3 randomised study of Dysport for treatment of upper limb spasticity (ULS) in adult patients had produced positive results. The study has proven Dysport's efficacy and safety in post-stroke or traumatic brain injury patients with ULS. It has met its primary and secondary endpoints in patients injected in different upper limb muscle groups, and has shown better efficacy on active movements, spasticity and passive function compared to placebo. Following the phase 3 study, Ipsen got in July the US Food and Drug Administration's approval of Dysport for treatment of ULS in the United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I7G:GR €52.59 EUR +0.52

I7G Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,194 JPY -1.00
H Lundbeck A/S kr190.00 DKK +0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation I7G Industry Range
Price/Earnings 31.6x
Price/Sales 3.1x
Price/Book 3.9x
Price/Cash Flow 31.6x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at